Geode Capital Management
KERX

Geode Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Geode Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,125,202
Closed -$3.83M – 4201
2018
Q3 		$3.83M Buy
1,125,202
+81,326
+8% +$293K ﹤0.01% 2532
2018
Q2 		$3.92M Buy
1,043,876
+117,168
+13% +$570K ﹤0.01% 2468
2018
Q1 		$3.79M Buy
926,708
+14,529
+2% +$67.7K ﹤0.01% 2415
2017
Q4 		$4.24M Buy
912,179
+19,003
+2% +$105K ﹤0.01% 2306
2017
Q3 		$6.34M Buy
893,176
+41,014
+5% +$295K ﹤0.01% 2056
2017
Q2 		$6.16M Buy
852,162
+43,375
+5% +$271K ﹤0.01% 2014
2017
Q1 		$4.98M Buy
808,787
+58,270
+8% +$319K ﹤0.01% 2118
2016
Q4 		$4.4M Buy
750,517
+27,501
+4% +$150K ﹤0.01% 2143
2016
Q3 		$3.84M Buy
723,016
+3,771
+0.5% +$20.3K ﹤0.01% 2130
2016
Q2 		$4.76M Buy
719,245
+19,350
+3% +$108K ﹤0.01% 1948
2016
Q1 		$3.27K Buy
699,895
+36,038
+5% +$144K ﹤0.01% 2144
2015
Q4 		$3.35M Buy
663,857
+6,711
+1% +$31.9K ﹤0.01% 2146
2015
Q3 		$2.31M Buy
657,146
+24,878
+4% +$167K ﹤0.01% 2351
2015
Q2 		$6.31M Buy
632,268
+5,236
+0.8% +$56.1K ﹤0.01% 1745
2015
Q1 		$7.98M Buy
627,032
+94,762
+18% +$1.22M ﹤0.01% 1553
2014
Q4 		$7.53M Buy
532,270
+9,288
+2% +$144K ﹤0.01% 1556
2014
Q3 		$7.19M Buy
522,982
+4,925
+1% +$75.4K ﹤0.01% 1513
2014
Q2 		$7.97M Buy
518,057
+25,016
+5% +$355K 0.01% 1472
2014
Q1 		$8.4M Buy
493,041
+100,735
+26% +$1.52M 0.01% 1375
2013
Q4 		$5.08M Buy
392,306
+42,350
+12% +$506K ﹤0.01% 1695
2013
Q3 		$3.54M Buy
349,956
+12,108
+4% +$108K ﹤0.01% 1811
2013
Q2 		$2.52M Buy
+337,848
New +$2.64M ﹤0.01% 1893

Geode Capital Management's KERX Position: Q4 2018 in Review

Geode Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 1,125,202 shares — an estimated $3.83M sold.

Geode Capital Management first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $8.4M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Geode Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Geode Capital Management sold 1,125,202 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $3.83M.
  • Geode Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
  • Geode Capital Management's Keryx Biopharmaceuticals Inc position peaked at $8.4M in Q1 2014.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Geode Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.